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CORRESPONDENCE
Letters to the Editor
The Mortality of Late Stent
Thrombosis in the Drug-Eluting
Stent Era—Still Underemphasized
Late stent thrombosis (LST) is an increasingly recognized com-
plication of drug-eluting stents (DES). Colombo and Corbett (1)
in their editorial in JACC summarized the evidence and provided
perspective. From the data it could be concluded that LST is not
overemphasized as has been suggested, but rather deserves more
attention. Although a very uncommon occurrence, LST has a
mortality of up to 45% (2). Long-term mandatory dual antiplatelet
therapy, although effective in reducing LST, carries its own risks
and is not an ideal solution. The advantage of DES over bare-
metal stents is only in the reduction of restenosis, an important
complication but not one carrying a significant risk of death (3). In
the absence of a clinical trial powered for mortality, the uncommon
complication of late stent thrombosis is of great importance, and
may mean that drug-eluting stents are not a better choice than
bare-metal stents.
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Reply
We thank Dr. Joshi for his interest in our editorial (1). Our aim
was not only to provide a perspective on the current state of play
in the field, but also to give our opinion as to where the balance of
evidence currently lies. In this regard, we believe that the reassur-
ance provided by the available follow-up data from randomized
trials (2,3) outweighs the understandable anxiety produced by
reports of stent thrombosis in case series and anecdotal reports (4,5).
On the basis of this we opted to use the word “overemphasized” in
the title. This is most definitely not to say that we believe this issue
should be underemphasized. Clearly, to exchange bare-metal stent
restenosis for drug-eluting stent thrombosis would be a major and
potentially catastrophic disservice to our patients. However, it
should be borne in mind that, contrary to the balloon angioplasty
data quoted by Dr. Joshi, in-stent restenosis is not always a benign
event; more than one-third of cases of restenosis in bare-metal
stents present as acute coronary events (6), whereas 2 of 23 patients
described in the study by Joner et al. (7) died of drug-eluting stent
restenosis. The issue of stent thrombosis in the drug-eluting stent
era is obviously one of considerable controversy. We have no doubt
that plenty of data are yet to emerge that will alternately fan and
quell the flames of this particular debate, providing it with the
attention and, more importantly, illumination that we all believe it
deserves.
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